Tirzepatide Dosage Protocol (5 mg, 10 mg, 15 mg Vials)
Quickstart Highlights
Tirzepatide is a 39–amino acid dual incretin receptor agonist that activates both GLP‑1 and GIP receptors, enhancing glucose‑dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite[1][2]. Its ~5‑day half‑life allows convenient once‑weekly subcutaneous dosing[1]. Clinical trials demonstrate superior glycemic control and weight reduction compared to selective GLP‑1 agonists[3][4].
- 5 mg Vial Reconstitution: Add 2.0 mL bacteriostatic water → 2.5 mg/mL concentration.
- 10 mg Vial Reconstitution: Add 2.0 mL bacteriostatic water → 5.0 mg/mL concentration.
- 15 mg Vial Reconstitution: Add 2.0 mL bacteriostatic water → 7.5 mg/mL concentration.
- Typical weekly range: 2.5–15 mg once weekly (gradual 4‑week titration steps).
- Easy measuring: At 2.5 mg/mL, 1 unit = 0.01 mL ≈ 25 mcg; at 5.0 mg/mL, 1 unit = 0.01 mL ≈ 50 mcg; at 7.5 mg/mL, 1 unit = 0.01 mL ≈ 75 mcg.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days.
Dosing & Reconstitution Guide
Educational guide for all vial sizes - choose your optimal concentration
Standard / Gradual Approach (All Vial Sizes)
| Phase | Weekly Dose | 5 mg Vial (Units) | 10 mg Vial (Units) | 15 mg Vial (Units) |
|---|---|---|---|---|
| Weeks 1–4 | 2.5 mg | 100 units (1.0 mL)* | 50 units (0.50 mL) | 33 units (0.33 mL) |
| Weeks 5–8 | 5 mg | 100 units × 2** | 100 units (1.0 mL) | 67 units (0.67 mL) |
| Weeks 9–12 | 7.5 mg | 100 units × 3** | 75 units × 2** | 100 units (1.0 mL) |
| Weeks 13–16 | 10 mg | 100 units × 4** | 100 units × 2** | 67 units × 2** |
*Doses requiring >1.0 mL (100 units) may need split injections or larger syringes.
**Multiple injections may be required; rotate injection sites.
Route: Subcutaneous injection. Frequency: Once weekly on a consistent day.
Concentration Reference: 5 mg vial: 2.5 mg/mL; 10 mg vial: 5.0 mg/mL; 15 mg vial: 7.5 mg/mL. Choose vial size based on your weekly dose requirements - larger vials provide better efficiency for higher dose protocols.
Reconstitution Steps (All Vial Sizes)
- Draw appropriate volume of bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- Use within 28 days of reconstitution[6].
Supplies Needed
Plan based on an 8–16 week protocol with gradual titration (once‑weekly dosing).
For All Vial Sizes
- Peptide Vials (Tirzepatide): Choose your preferred vial size (5 mg, 10 mg, or 15 mg).
- Insulin Syringes (U‑100, 1 mL):
- 8 weeks: 8‑12 syringes (depending on vial size)
- 12 weeks: 12‑24 syringes (depending on vial size)
- 16 weeks: 16‑40 syringes (depending on vial size)
- Bacteriostatic Water (10 mL bottles): Volume depends on vial size and reconstitution.
- Alcohol Swabs: One for the vial stopper + one for the injection site each administration day.
- Per week: 2 swabs (1 injection day)
- 8 weeks: 16 swabs → recommend 1 × 100‑count box
- 12 weeks: 24 swabs → recommend 1 × 100‑count box
- 16 weeks: 32 swabs → recommend 1 × 100‑count box
Protocol Overview
Concise summary of the once‑weekly regimen.
- Goal: Support glycemic control, weight management, and metabolic health through dual incretin receptor activation[2].
- Schedule: Weekly subcutaneous injection on the same day each week for 12–16+ weeks.
- Dose Range: 2.5–15 mg weekly with 4‑week titration intervals.
- Vial Options: 5 mg, 10 mg, or 15 mg vials with optimized reconstitution for each size.
- Storage: Lyophilized frozen; reconstituted refrigerated for up to 28 days.
Dosing Protocol
Suggested weekly titration approach.
- Start: 2.5 mg once weekly for 4 weeks (initiation dose)[1].
- Escalate: Increase by 2.5 mg every 4 weeks as tolerated.
- Maintenance: 5–15 mg weekly based on response and tolerability.
- Frequency: Once per week (subcutaneous), same day each week.
- Timing: Any time of day; with or without food; rotate injection sites.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze reconstituted solution[6].
- Shelf life: Use reconstituted solution within 28 days[6].
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes; dispose in a sharps container[7].
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation[8].
- For multi‑injection doses, use different sites for each injection on the same day.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document weekly dose, date, and injection site to maintain consistency.
- Gastrointestinal effects (nausea, diarrhea) are common initially; gradual titration helps minimize them[1].
- For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
How This Works
Tirzepatide is a novel dual agonist that simultaneously activates GLP‑1 (glucagon‑like peptide‑1) and GIP (glucose‑dependent insulinotropic polypeptide) receptors[1][2]. This dual mechanism enhances glucose‑dependent insulin secretion while suppressing glucagon release, slowing gastric emptying, and promoting satiety through central appetite regulation[2]. The added GIP activity appears to synergistically amplify metabolic effects beyond GLP‑1 alone, contributing to superior weight reduction observed in clinical trials[3][4]. Its ~5‑day half‑life enables convenient once‑weekly administration[1].
Potential Benefits & Side Effects
Observations from clinical trials and published literature.
- Glycemic control: Significant HbA1c reductions in type 2 diabetes trials[4][9].
- Weight reduction: Clinical trials report substantial body‑weight loss (up to ~11 kg more than GLP‑1 RA comparators over 26 weeks at higher doses)[3][4].
- Cardiovascular markers: Improvements in lipid profiles and blood pressure observed in some studies[9].
- Common side effects: Gastrointestinal (nausea, diarrhea, vomiting, constipation) — typically mild‑to‑moderate and dose‑dependent; gradual titration reduces incidence[1][5].
- Injection‑site reactions: Occasional mild redness or irritation at subcutaneous injection sites.
Lifestyle Factors
Complementary strategies for best outcomes.
- Pair with a balanced, calorie‑appropriate diet; reduced appetite may naturally decrease intake.
- Prioritize protein to preserve lean mass during weight loss.
- Combine resistance training and aerobic activity to support metabolic health.
- Stay hydrated, especially given potential gastrointestinal effects.
- Prioritize sleep and stress management to support adherence and recovery.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[8][10].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[8][10].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[10].
- Rotate sites systematically (abdomen avoiding 2‑inch radius around navel, outer thighs, upper arms) to avoid lipohypertrophy[8].
- Dispose of needles and syringes in a sharps container immediately after use[7].
Recommended Source
We recommend Legion Peptides for high‑purity Tirzepatide in all vial sizes (5 mg, 10 mg, 15 mg).
Why Legion Peptides?
- High‑purity, third‑party‑tested lots with batch COAs.
- Consistent, ISO‑aligned handling and documentation.
- Reliable fulfillment to maintain cold‑chain integrity.
- Multiple vial sizes to match different protocol needs.
Important Note
This content is for educational purposes only and is not medical advice. Tirzepatide is for research use only. Not for human consumption. Always consult with qualified professionals before starting any peptide research protocol.
References
- StatPearls (NCBI Bookshelf) — Farzam K, Patel P. Tirzepatide. StatPearls Publishing; 2024. Comprehensive overview of pharmacology, dosing, and clinical use.
- Frontiers in Endocrinology — Gallwitz B. GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes and obesity. Front Endocrinol. 2022;13:1004044.
- The Lancet — Frias JP, et al. Efficacy and safety of LY3298176 (tirzepatide), a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes (Phase 2 trial). Lancet. 2018;392(10160):2180-2193.
- New England Journal of Medicine — Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.
- FDA Prescribing Information — Mounjaro (tirzepatide) injection Prescribing Information. Eli Lilly and Company; 2022.
- GobyMeds Pharmacy — Does Compounded Tirzepatide Need To Be Refrigerated? Storage guidelines for reconstituted peptides.
- CDC Injection Safety — Preventing Unsafe Injection Practices. Guidelines for multi-dose vials and safe needle disposal.
- MedlinePlus Medical Encyclopedia — Subcutaneous (SQ) injections: Technique, site rotation, and best practices.
- Mayo Clinic — Tirzepatide (Subcutaneous route) – Drugs and Supplements. Clinical overview and patient information.
- CDC Vaccine Administration — Subcutaneous injection technique: angle, site selection, and no aspiration guidance.
